Antitumor response against myeloma cells by immunization with mouse syngenic dendritoma.
In order to generate an immune response against myeloma cells in an homogenous murine model, a stable hybrid cell line (DCSp) was established through the syngenic fusion between mouse dendritic cells (DC) and mouse Sp2/0 myeloma cells. DCSp cells behaved as potent T cell stimulators and were able to induce Sp2/0 specific cytotoxicity. When mice were immunized with irradiated hybrids before SP2/0 injection, they exhibited a significantly higher rate of survival as compared with controls. When tumors were detected, their emergence was not delayed, and time elapsed between tumor clinical perception and death remained unchanged. A humoral immune response was also always associated. We assume that this stable dendritoma cell line can be considered a valuable tool for myeloma studies in an homogenous mouse model. The efficiency of dendritoma as a weapon against tumor cells and the benefit of syngeny in experimental models are discussed.
Quéant
S
S
Immunocytologie et Oncologie Moléculaire, Université de Technologie de Compiègne, Compiègne, France.
Sarde
C-O
CO
Gobert
M-G
MG
Kadouche
J
J
Roseto
A
A
D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology*; D002455:Cell Division; D003713:Dendritic Cells / Q000276:immunology*; D006825:Hybridomas; D051379:Mice; D008807:Mice, Inbred BALB C; D008854:Microscopy, Electron; D009101:Multiple Myeloma / Q000276:immunology* / Q000473:pathology; D013602:T-Lymphocytes, Cytotoxic / Q000166:cytology
D019496:Cancer Vaccines